title: Reply to A. Addeo and A. Bahl.
authors.affiliation: Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY scherh@mskcc.org.
authors.forename: Howard I
authors.initials: HI
authors.lastname: Scher
authors.affiliation: Memorial Sloan Kettering Cancer Center, New York, NY.
authors.forename: Glenn
authors.initials: G
authors.lastname: Heller
authors.affiliation: Janssen Research & Development, Menlo Park, CA.
authors.forename: Arturo
authors.initials: A
authors.lastname: Molina
authors.affiliation: Janssen Research & Development, San Diego, CA.
authors.forename: Thian
authors.initials: T
authors.lastname: Kheoh
authors.affiliation: The Institute of Cancer Research and The Royal Marsden Hospital, Sutton, Surrey, United Kingdom.
authors.forename: Johann S
authors.initials: JS
authors.lastname: de Bono
mesh_terms: D000736:Androstenes / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000032:analysis*; D006801:Humans; D008297:Male; D009360:Neoplastic Cells, Circulating / Q000473:pathology*; D064129:Prostatic Neoplasms, Castration-Resistant / Q000473:pathology*
chemical_list: D000736:Androstenes; D014408:Biomarkers, Tumor